Critical Parameters for the Development of Novel Therapies for Severe and Resistant Infections—A Case Study on CAL02, a Non-Traditional Broad-Spectrum Anti-Virulence Drug
Background: Poor outcomes in severe and resistant infections, together with the economic struggles of companies active in the field of anti-infective development, call for new solutions and front runners with novel approaches. Among “non-traditional” approaches, blocking virulenc...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-02-01
|
| Series: | Antibiotics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-6382/9/2/94 |
| _version_ | 1818035720225292288 |
|---|---|
| author | Samareh Azeredo da Silveira Andrew F. Shorr |
| author_facet | Samareh Azeredo da Silveira Andrew F. Shorr |
| author_sort | Samareh Azeredo da Silveira |
| collection | DOAJ |
| description | Background: Poor outcomes in severe and resistant infections, together with the economic struggles of companies active in the field of anti-infective development, call for new solutions and front runners with novel approaches. Among “non-traditional” approaches, blocking virulence could be a game changer. Objectives: This review offers a perspective on parameters that have determined the development path of CAL02, a novel anti-virulence agent, with a view to steering clear of the obstacles and limitations that impede market sustainability for new anti-infective drugs. Conclusions and implications of key findings: This case study highlights four pillars that may support the development of other non-traditional drugs and, concurrently, provide a new model that could reshape the field. Therapeutic triggers, study designs, and economic parameters are discussed. |
| first_indexed | 2024-12-10T06:59:32Z |
| format | Article |
| id | doaj.art-ee7995ec43164498b9f198e948cd4646 |
| institution | Directory Open Access Journal |
| issn | 2079-6382 |
| language | English |
| last_indexed | 2024-12-10T06:59:32Z |
| publishDate | 2020-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibiotics |
| spelling | doaj.art-ee7995ec43164498b9f198e948cd46462022-12-22T01:58:22ZengMDPI AGAntibiotics2079-63822020-02-01929410.3390/antibiotics9020094antibiotics9020094Critical Parameters for the Development of Novel Therapies for Severe and Resistant Infections—A Case Study on CAL02, a Non-Traditional Broad-Spectrum Anti-Virulence DrugSamareh Azeredo da Silveira0Andrew F. Shorr1Combioxin SA, 8 rue de la Rôtisserie, 1204 Geneva, SwitzerlandPulmonary and Critical Care Medicine, Medstar Washington Hospital Center, Washington, DC 20010, USABackground: Poor outcomes in severe and resistant infections, together with the economic struggles of companies active in the field of anti-infective development, call for new solutions and front runners with novel approaches. Among “non-traditional” approaches, blocking virulence could be a game changer. Objectives: This review offers a perspective on parameters that have determined the development path of CAL02, a novel anti-virulence agent, with a view to steering clear of the obstacles and limitations that impede market sustainability for new anti-infective drugs. Conclusions and implications of key findings: This case study highlights four pillars that may support the development of other non-traditional drugs and, concurrently, provide a new model that could reshape the field. Therapeutic triggers, study designs, and economic parameters are discussed.https://www.mdpi.com/2079-6382/9/2/94severe infectionspneumoniavirulencebroad-spectrumnontraditionaltoxinsendpoint |
| spellingShingle | Samareh Azeredo da Silveira Andrew F. Shorr Critical Parameters for the Development of Novel Therapies for Severe and Resistant Infections—A Case Study on CAL02, a Non-Traditional Broad-Spectrum Anti-Virulence Drug Antibiotics severe infections pneumonia virulence broad-spectrum nontraditional toxins endpoint |
| title | Critical Parameters for the Development of Novel Therapies for Severe and Resistant Infections—A Case Study on CAL02, a Non-Traditional Broad-Spectrum Anti-Virulence Drug |
| title_full | Critical Parameters for the Development of Novel Therapies for Severe and Resistant Infections—A Case Study on CAL02, a Non-Traditional Broad-Spectrum Anti-Virulence Drug |
| title_fullStr | Critical Parameters for the Development of Novel Therapies for Severe and Resistant Infections—A Case Study on CAL02, a Non-Traditional Broad-Spectrum Anti-Virulence Drug |
| title_full_unstemmed | Critical Parameters for the Development of Novel Therapies for Severe and Resistant Infections—A Case Study on CAL02, a Non-Traditional Broad-Spectrum Anti-Virulence Drug |
| title_short | Critical Parameters for the Development of Novel Therapies for Severe and Resistant Infections—A Case Study on CAL02, a Non-Traditional Broad-Spectrum Anti-Virulence Drug |
| title_sort | critical parameters for the development of novel therapies for severe and resistant infections a case study on cal02 a non traditional broad spectrum anti virulence drug |
| topic | severe infections pneumonia virulence broad-spectrum nontraditional toxins endpoint |
| url | https://www.mdpi.com/2079-6382/9/2/94 |
| work_keys_str_mv | AT samarehazeredodasilveira criticalparametersforthedevelopmentofnoveltherapiesforsevereandresistantinfectionsacasestudyoncal02anontraditionalbroadspectrumantivirulencedrug AT andrewfshorr criticalparametersforthedevelopmentofnoveltherapiesforsevereandresistantinfectionsacasestudyoncal02anontraditionalbroadspectrumantivirulencedrug |